Common Contracts
8 similar Registration Rights Agreement contracts by Cell Therapeutics Inc, Acquicor Technology Inc, Curagen Corp, Immunomedics Inc
Form 29 Registration Rights AgreementRegistration Rights Agreement • June 30th, 2022 • New York
[Company], a [Delaware] corporation (the “Company”), proposes to issue and sell to the initial purchaser named in the purchase agreement (the “Initial Purchaser”), upon the terms set forth in such purchase agreement dated [Month] __, 20__ (the “Purchase Agreement”), its __% Convertible [Semior] [Subordinated] Notes due 20__ (the “Securities”). As an inducement to the Initial Purchaser to enter into the Purchase Agreement and in satisfaction of a condition to the obligations of the Initial Purchaser thereunder, the Company agrees with the Initial Purchaser for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
CELL THERAPEUTICS, INC. REGISTRATION RIGHTS AGREEMENT December 12, 2007Registration Rights Agreement • December 13th, 2007 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
Cell Therapeutics, Inc., a corporation organized under the laws of the State of Washington (the “Company”), proposes to exchange the Outstanding Notes (as defined in the Exchange Agreement) held by the investors listed on each Schedule 1 (the “Investors”) of the respective Exchange Agreements (the “Exchange Agreement”), dated December 11, 2007, by and between the Investors and the Company and signatory hereto, for an additional number of shares of Common Stock set forth opposite such Investor’s name under the column “Number of Common Shares” on Schedule 1 thereto (such shares being referred to herein as the “Exchange Shares”) and the principal amount of 5.75% Convertible Senior Notes due 2011 issued under an indenture substantially in the form set forth on Exhibit A of the Exchange Agreement set forth opposite such Investor’s name under the column “Aggregate Principal Amount of Exchange Notes” on Schedule 1 thereto (such notes being referred to herein as the “Exchange Notes”, and colle
ACQUICOR TECHNOLOGY INC. 8% CONVERTIBLE SENIOR NOTES DUE 2011 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 22nd, 2006 • Acquicor Technology Inc • Blank checks • New York
Acquicor Technology Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to issue to CRT Capital Group LLC and Needham & Company, LLC (the “Initial Purchasers”), pursuant to the Purchase Agreement, dated December 18, 2006 (the “Purchase Agreement”), among the Initial Purchasers and the Company, $145,000,000 aggregate principal amount (plus up to an additional $21,750,000 aggregate principal amount) of its 8% Convertible Senior Notes due 2011 (the “Securities”) upon the terms and subject to the conditions set forth in such Purchase Agreement. The Securities will be convertible into shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at the initial conversion rate of 136.426 shares of Common Stock per each $1,000 principal amount of Securities, subject to adjustment in certain circumstances. The Securities will be issued pursuant to an Indenture dated as of December 19, 2006 (the “Indenture”), among the Compan
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 18th, 2006 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
Cell Therapeutics, Inc., a corporation organized under the laws of the State of Washington (the “Company”), proposes to issue the Securities (as defined below) to Novartis Pharma AG, a corporation organized under the laws of Switzerland (the “Investor”), upon the terms and subject to the conditions set forth in that certain Securities Purchase Agreement dated the date hereof by and between the Investor and the Company (the “Securities Purchase Agreement”). As an inducement to the Investor to enter into the Securities Purchase Agreement and in satisfaction of a condition to the obligations of the Investor thereunder, the Company agrees with the Investor for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
CELL THERAPEUTICS, INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 28th, 2006 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
Cell Therapeutics, Inc., a corporation organized under the laws of the State of Washington (the “Company”), proposes to issue to the investors listed on Schedule I (the “Investors”) of the Exchange Agreement, dated April 24, 2006, by and among the Investors and the Company (the “Exchange Agreement”) and signatory hereto, its 7.5% Convertible Senior Notes due 2011 (the “Securities”) upon the terms and subject to the conditions set forth in such Exchange Agreement. As an inducement to the Initial Purchaser to enter into the Purchase Agreement and the Investors to enter into the Exchange Agreement and in satisfaction of conditions to the obligations of the Initial Purchaser and the Investors thereunder, the Company agrees with the Initial Purchaser and the Investors for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
CELL THERAPEUTICS, INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 10th, 2005 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
Cell Therapeutics, Inc., a corporation organized under the laws of the State of Washington (the “Company”), proposes to issue and sell to the initial purchaser (the “Initial Purchaser”) named in the Purchase Agreement, dated October 31, 2005, by and between the Initial Purchaser and the Company (the “Purchase Agreement”), its 6.75% Convertible Senior Notes due 2010 (the “Securities”) and warrants to purchase 350,000 shares of its Common Stock (the “Warrant”), upon the terms and subject to the conditions set forth in such Purchase Agreement. As an inducement to the Initial Purchaser to enter into the Purchase Agreement and in satisfaction of a condition to the obligations of the Initial Purchaser thereunder, the Company agrees with the Initial Purchaser for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
Immunomedics, Inc.Registration Rights Agreement • April 23rd, 2004 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Immunomedics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the purchaser named in the purchase agreement (the “Initial Purchaser”), upon the terms set forth in such purchase agreement dated January 12, 2004 (the “Purchase Agreement”), its 3.25% Convertible Senior Notes due 2006 (the “Securities”). As an inducement to the Initial Purchaser to enter into the Purchase Agreement and in satisfaction of a condition to the obligations of the Initial Purchaser thereunder, the Company agrees with the Initial Purchaser for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
CURAGEN CORPORATION REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 11th, 2004 • Curagen Corp • Services-commercial physical & biological research • New York
CuraGen Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the initial purchaser named in the purchase agreement (the “Initial Purchaser”), upon the terms set forth in such purchase agreement dated February 10, 2004 (the “Purchase Agreement”), its 4.0% Convertible Subordinated Notes due 2011 (the “Securities”). As an inducement to the Initial Purchaser to enter into the Purchase Agreement and in satisfaction of a condition to the obligations of the Initial Purchaser thereunder, the Company agrees with the Initial Purchaser for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
